1[1]Ganz T. Defensins: antimicrobial peptides of innate immunity [J]. Nat Rev Immunol,2003,3(9):710-720.
2[2]Goldman MJ, Anderson GM, Stolzenberg ED, et al. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis[J]. Cell,1997,88(4):553-560.
3[3]Tomita T, Nagase T, Ohga E, et al. Molecular mechanisms underlying human beta-defensin-2 gene expression in a human airway cell line (LC2/ad)[J]. Respirology, 2002 ,7(4):305-310.
4[4]Harder J, Bartels J, Christophers E, et al. A peptide antibiotic from human skin[J].Nature,1997,387(6636):861.
5[5]Huang GT, Zhang HB, Kim D, et al. A model for antimicrobial gene therapy: demonstration of human beta-defensin 2 antimicrobial activities in vivo[J]. Hum Gene Ther, 2002,13(17):2017-2025.
6[7]Mangtani P, Cutts F, Hall AJ. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence[J]. Lancet Infect Dis, 2003,3(2):71-78.
7[8]Srivastava IK, Liu MA. Gene vaccines[J]. Ann Intern Med, 2003 ,138(7):550-559.
8[9]Beachey EH. Bacterial adherence: adhesin-receptor interactions mediating the attachment of bacteria to mucosal surface[J]. J Infect Dis,1981,143(3):325-345.
9[10]Thomas RJ, Brooks TJ. Oligosaccharide receptor mimics inhibit Legionella pneumophila attachment to human respiratory epithelial cells[J]. Microb Pathog, 2004,36(2):83-92.
10[12]Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis[J]. Chest, 1992,101(6):1644-1655.
